loading
Entrada Therapeutics Inc stock is traded at $17.93, with a volume of 64,645. It is up +0.90% in the last 24 hours and up +2.81% over the past month. Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
See More
Previous Close:
$17.77
Open:
$17.72
24h Volume:
64,645
Relative Volume:
0.49
Market Cap:
$670.94M
Revenue:
$239.40M
Net Income/Loss:
$104.44M
P/E Ratio:
-6.9496
EPS:
-2.58
Net Cash Flow:
$-18.50M
1W Performance:
-10.17%
1M Performance:
+2.81%
6M Performance:
+17.04%
1Y Performance:
+9.93%
1-Day Range:
Value
$17.52
$17.94
1-Week Range:
Value
$17.09
$20.25
52-Week Range:
Value
$10.75
$20.49

Entrada Therapeutics Inc Stock (TRDA) Company Profile

Name
Name
Entrada Therapeutics Inc
Name
Phone
857-305-1825
Name
Address
ONE DESIGN CENTER PLACE, BOSTON
Name
Employee
177
Name
Twitter
Name
Next Earnings Date
2024-08-12
Name
Latest SEC Filings
Name
TRDA's Discussions on Twitter

Compare TRDA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
TRDA 17.93 670.94M 239.40M 104.44M -18.50M -2.58
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-05-24 Initiated Oppenheimer Outperform
Apr-03-23 Initiated H.C. Wainwright Buy

Entrada Therapeutics Inc Stock (TRDA) Latest News

pulisher
Nov 17, 2024

Los Angeles Capital Management LLC Makes New $542,000 Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat

Nov 17, 2024
pulisher
Nov 15, 2024

Insider Sale at Entrada Therapeutics Inc (TRDA) by President of Research & Development - GuruFocus.com

Nov 15, 2024
pulisher
Nov 13, 2024

500: Something went wrong - Investing.com UK

Nov 13, 2024
pulisher
Nov 11, 2024

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 11, 2024
pulisher
Nov 10, 2024

HC Wainwright Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - Defense World

Nov 10, 2024
pulisher
Nov 08, 2024

HC Wainwright Analysts Boost Earnings Estimates for TRDA - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World

Nov 08, 2024
pulisher
Nov 07, 2024

Entrada Therapeutics president sells shares worth $339,280 By Investing.com - Investing.com Australia

Nov 07, 2024
pulisher
Nov 07, 2024

Equities Analysts Issue Forecasts for TRDA FY2024 Earnings - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

HC Wainwright Has Positive Outlook of TRDA FY2024 Earnings - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock - Benzinga

Nov 06, 2024
pulisher
Nov 06, 2024

Oppenheimer Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Entrada Therapeutics stock target increased on positive trial data By Investing.com - Investing.com UK

Nov 06, 2024
pulisher
Nov 06, 2024

Entrada Therapeutics (NASDAQ:TRDA) Price Target Raised to $20.00 - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 06, 2024
pulisher
Nov 05, 2024

Entrada Therapeutics’ Q3 2024 Financial Highlights - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Entrada Therapeutics (NASDAQ:TRDA) Hits New 12-Month HighHere's What Happened - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Entrada Therapeutics stock hits 52-week high at $18.22 By Investing.com - Investing.com UK

Nov 05, 2024
pulisher
Nov 05, 2024

Entrada Therapeutics : Corporate Presentation - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

Entrada Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 05, 2024
pulisher
Nov 02, 2024

Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going - MSN

Nov 02, 2024
pulisher
Oct 28, 2024

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Short Interest Down 19.1% in October - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Short Interest in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Declines By 19.1% - Defense World

Oct 28, 2024
pulisher
Oct 19, 2024

Here's What Could Help Entrada Therapeutics (TRDA) Maintain Its Recent Price Strength - MSN

Oct 19, 2024
pulisher
Oct 19, 2024

Entrada Therapeutics president sells $10,800 in stock By Investing.com - Investing.com Australia

Oct 19, 2024
pulisher
Oct 18, 2024

Natarajan Sethuraman Sells 600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding - Simply Wall St

Oct 17, 2024
pulisher
Oct 15, 2024

Oppenheimer Initiates Coverage of Entrada Therapeutics (TRDA) with Outperform Recommendation - MSN

Oct 15, 2024
pulisher
Oct 14, 2024

(TRDA) Trading Report - Stock Traders Daily

Oct 14, 2024
pulisher
Oct 14, 2024

The Manufacturers Life Insurance Company Purchases 2,146 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World

Oct 14, 2024
pulisher
Oct 10, 2024

Renaissance Technologies LLC Invests $636,000 in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Entrada Therapeutics advances Duchenne treatment trials - Investing.com

Oct 09, 2024
pulisher
Oct 09, 2024

Entrada Therapeutics advances Duchenne treatment trials By Investing.com - Investing.com UK

Oct 09, 2024
pulisher
Oct 09, 2024

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society - The Manila Times

Oct 09, 2024
pulisher
Oct 09, 2024

HRMY: 3 Small-Cap Biotech Stocks to Buy for Major Upside - StockNews.com

Oct 09, 2024
pulisher
Oct 03, 2024

(TRDA) Trading Advice - Stock Traders Daily

Oct 03, 2024
pulisher
Oct 01, 2024

Morguard Un (MRT-UN-T) QuotePress Release - The Globe and Mail

Oct 01, 2024
pulisher
Oct 01, 2024

Pompe Disease Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Market Dynamics, MOA, ROA by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas - The Globe and Mail

Oct 01, 2024
pulisher
Oct 01, 2024

Entrada Therapeutics COO sells shares worth over $13,000 - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

Entrada Therapeutics COO sells shares worth over $13,000 By Investing.com - Investing.com Australia

Oct 01, 2024
pulisher
Sep 30, 2024

Insider Sale: President & COO Nathan Dowden Sells Shares of Entr - GuruFocus.com

Sep 30, 2024
pulisher
Sep 27, 2024

Entrada Therapeutics (NASDAQ:TRDA) Trading 4.8% Higher - MarketBeat

Sep 27, 2024
pulisher
Sep 25, 2024

U.S. Gold Corp (USAU-Q) QuotePress Release - The Globe and Mail

Sep 25, 2024
pulisher
Sep 24, 2024

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development - Markets Insider

Sep 24, 2024
pulisher
Sep 24, 2024

Entrada Therapeutics appoints new President of R&D - Investing.com

Sep 24, 2024
pulisher
Sep 23, 2024

TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch

Sep 23, 2024

Entrada Therapeutics Inc Stock (TRDA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):